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Abstract
Uncovering the mode of electron transport within the 3-ketosteroid-9𝛼-hydroxylase, KshAB,
enzyme complex from Mycobacterium tuberculosis will reveal previously unknown possibilities
towards curing tuberculosis infections. The KshB protein was mutated at one possible site of
electron transfer – an arginine at location 286 – to rupture its cooperation with the KshA complex
to prevent the bacteria from gaining energy from the breakdown of steroids as a fuel source. The
arginine was mutated to an aspartic acid and alanine to get varying chemical properties to replace
the original amino acid. Experimentation included over-expressing the wildtype and mutant
proteins in E. coli, purifying them through Nickel-NTA column chromatography, and analyzing
them for size and purity through SDS-PAGE. The kinetics of KshA and mutant KshB proteins’
electron transfer were quantified through UV-vis kinetic analysis and utilizing the MichaelisMenten equation to extrapolate the kinetic parameters, KM, Vmax, and kcat. Data collected from
these experiments were used to compare the wtKshA/KshB-R286D mutant to the wildtype KshAB
data to determine whether or not the mutation disrupted the electron transfer between the two
subunits. It was concluded based off of the kinetic data that the rate at which the mutant KshAB
enzyme hydroxylates a steroid structure is significantly lower than that of the wildtype KshAB
complex. This leads to the observation that the site of mutation is crucial to the electron transfer
pathway between the enzyme’s subunits. The overall function is not completely inhibited, but it is
decreased significantly enough to assume a successful outcome. Obstructing the interaction
between the A and B subunits effectively can open pathways towards a new antibiotic treatment
for TB by targeting the bacteria’s mechanism for energy production, benefitting the
pharmaceutical industry, medical field, and those infected or at risk of TB infection.
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Introduction
Strep throat, meningitis, food poisoning, chlamydia, pink eye, tuberculosis: all of these illnesses
seem unrelated, but they all have one thing in common – they are all infections caused by bacteria.
Bacteria can be beneficial and detrimental for our bodies all in one. There are “good” bacteria such
as lactobacillus, a probiotic found within both yogurt and our digestive tract that helps us convert
sugars to lactic acid (1). An example of a “bad” type of bacteria is Clostridium tetani, which can
be found in soil or dust and causes tetanus by entering our bodies through wounds. However, there
are bacteria than can be both “good” and bad”, such as Escherichia coli, is abundant within our
digestive system and helps to breakdown food. Once it enters a different part of our body, it can
cause an infection since it is not in its normal environment. This is the cause of pink eye and some
types of pneumonia (2).

Although the distinction between “good” and “bad” bacteria can be difficult to discern, the way
they infect humans is fairly straightforward. The two main modes of transmission are direct and
indirect. Direct transmission happens when there is contact between a host of the bacteria and those
susceptible. On the contrary, indirect transmission occurs when bacteria are present in the
environment and a susceptible host is infected through interaction with the environment, not
another host (3). There are two types of direct transmission: direct contact and droplet spread.
Direct contact requires skin-to-skin contact, kissing, or sexual intercourse (4). Gonorrhea is a good
example of this. Droplet transmission can be spread through talking, a cough, or a sneeze (4). The
host can directly “spray” microbes onto a susceptible host before the droplets fall to the ground.
In light of the current situation, this happens to be the main mode of transmission for COVID-19,
which is why face masks are encouraged (5). Although it’s a virus, both bacteria and viruses have
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similar methods of spread. Indirect transmission has three subsets: airborne, vehicle-borne, and
vector-borne. Vehicle-borne transmission is when a bacterium is transmitted through objects, such
as water as a mode of transmission for Cholera (4). Vector-borne infections are those transmitted
but not caused by an intermediary, such as mosquitoes or ticks in Eastern Equine Encephalitis
(EEE) and Lyme Disease (4). Airborne pathogens, on the other hand, have a simple pathway to
contagion; as soon as a person who is infected coughs, sneezes, spits, or even breathes, the bacteria
are propelled into the air and all one has to do to become infected is breathe in the same air,
allowing the bacteria to colonize in their lungs. There are varying size limits to be considered a
droplet, anywhere from 2 to 10 to 100 micrometers depending on many factors as it is believed
that particles less than 60 micrometers in diameter evaporate before reaching the ground (6). This
is different from droplet transmission since airborne pathogens are typically held in particles
smaller than 5 micrometers in size (4). COVID-19 can vary in size, anywhere between 60 and 140
nanometers, which is why it is considered to be a virus that is transmitted through droplets (7).
Tuberculosis, in contrast, is an excellent example of an airborne pathogen thanks to its small size.
Knowing the mode of transmission is essential for the treatment and prevention of every infection.

Mycobacterium tuberculosis is a type of bacteria known to infect humans and consequently affect
many organs. M. tuberculosis causes the highly contagious disease of tuberculosis (TB), which
causes a patient to experience symptoms including a cough, fever, blood-tinged sputum, and
unexplained weight loss. The lungs are most commonly affected by TB, which is the deadliest
infectious disease at this time, on average killing 1.6 million every year (8). TB is easily spread
since it is an airborne-transmitted pathogen. Although its origins are unknown, antibiotic drugs
became available to treat the disease in the 1950s, back when TB was named "consumption”. It
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was given this name since a common symptom was dramatic weight loss. Before antibiotics were
discovered, one-third of all deaths in America were caused by three diseases: pneumonia, enteritis,
and tuberculosis (9). TB on its own was the cause of more than 10% of those mortalities (9).

The modern treatment of tuberculosis started in 1944 when penicillin, an antibiotic, was discovered
that successfully controlled and eradicated the spread of TB (10). Antibiotics are used to remove
bacterial cells and are necessary to fight strong infections such as TB since a human’s immune
system is not sufficient enough on its own. The number of possible antibiotic treatments for TB
expanded, and all had been relatively successful until the M. tuberculosis bacteria evolved to
become resistant to varying types of antibiotics, meaning that the bacteria could no longer be
exterminated. Bacteria, similar to every other living organism, evolve when certain traits are
favorable for their ability to survive. This is why strains with mutations which allow it to live past
antibiotic treatment are more fit than those without it, as this gained trait allows for more successful
reproduction since they avoid death. There are two types of resistant TB infections: MDR (multidrug resistant) and XDR (extensively drug-resistant). In 2016, 19% of all TB cases were caused
by the MDR strains, along with 9.6% of patients who had the XDR strains (8,11). Malaria and
Methicillin-resistant Staphylococcus aureus (MRSA) are both MDR diseases, but TB happens to
be one of the most prevalent cases of drug resistance. Patients with HIV/AIDS, who have their
immune systems compromised, are at a higher likelihood of gaining XDR-TB than those without
HIV/AIDS since their immune systems are inherently weakened. They have a much harder time
getting treatment as well, and since M. tuberculosis in those strains are resistant to the most
commonly used antibiotics for treatment of TB, their chances of survival are slim. In patients
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coinfected with HIV, there’s a mortality rate of 63% for those who have MDR-TB versus a
mortality rate of 80% of those infected with XDR-TB, for example (12).

It has been found that within the human body, Mycobacterium tuberculosis flourishes by breaking
down the steroid structures of cholesterol and using that as their energy source (13), which
ultimately increases the bacteria’s chance of survival and also increases a patient’s chance of not
being cured. Studies have been done on TB bacteria that enlightened this pathway of survival, and
there is evidence that shows the importance of the enzyme 3-ketosteroid 9𝛼-hydroxylase (KSH)
in the cholesterol degradation pathway (Figure 1). KSH is an enzyme that contains two domains,
KshA and KshB. KshA is an oxygenase, which is an enzyme that oxidizes (takes electrons from)
a compound by adding an -OH group, while KshB is a reductase that provides electrons to KshA
(13).
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Figure 1. The catabolic pathway of cholesterol breakdown within several bacteria,
including Mycobacterium tuberculosis. This diagram shows the entirety of the metabolism
of cholesterol, specifically showcasing the side-chain degradation and ring-opening steps.
KshAB is shown near the dashed brackets, which indicate that the compound undergoes
nonenzymatic hydrolysis after KshAB performs hydroxylation at the 9-position of the
steroid B-ring intermediate (13).

KshA has three parts that together form a circular structure called a trimer (Figure 2). KshB is a
one-component reductase, which instead takes electrons from a compound to reduce another.
Specifically, electrons from nicotinamide adenine dinucleotide (NADH, a common electron
donor) will be taken, given to another electron donor compound known as flavin adenine
dinucleotide (FAD), then sent to a plant-type iron-sulfur cluster (Fe2S2) in KshB, and all electrons
will eventually be passed through to a Rieske-type iron-sulfur cluster (Fe2S2) in one subunit of
KshA (Figure 3). Those electrons are finally passed to the non-heme iron center in another subunit
of KshA. Together, the two enzymes are able to catalyze the hydroxylation (addition of an -OH)
of a 3-ketosteroid (Figure 4). This leads to the opening of the B-ring within the cholesterol structure
(13), further downstream in the overall cholesterol catabolic pathway (Figure 1). If the KshA and
KshB subunits are removed from an organism of M. tuberculosis, it would blunt the metabolic
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pathway and bacteria would break down steroid ring structures at a lower rate. This could allow
for more successful treatment of TB since the bacteria would reproduce slower and therefore the
onset of infection would be elongated, giving doctors a longer treatment window before the
infection becomes too overwhelming within the body. The two domains are therefore essential for
the active infection of TB in humans (14) and preventing their interaction could bring a unique
cure for the disease.

Figure 2. Structural model of the KshAB enzyme complex, including the KshA trimer with
the KshB monomer. The KshA trimer is depicted in pink, white, and purple, with each
color being a different subunit. The KshA structure is from the PDB file 4QCK (15). The
KshB subunit is shown in green interacting with one of the subunits. The KshB structure
was determined using the Phyre2 (16) server and a model of phthalate dioxygenase
reductase (17). Interactions between KshA and KshB were predicted using the ClusPro
server for protein-protein docking (18). It is believed that there are three KshB subunits,
one interacting with each of KshA’s respective subunits.
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Figure 3. Diagram of the KshAB complex, including the KshA trimer, that shows the mode
of electron transfer. Electrons travel from NADH to KshB, via the iron-sulfur cluster, then
to KshA to catalyze the addition of an -OH group to the ketosteroid (19).

B

B

Figure 4. Structure of the 3-ketosteroid that KshAB works on, along with a reaction
schematic showing the addition of the -OH group onto the ketosteroid creating a 9𝛼hydroxyl group. The B identifies the ring within the cholesterol structure that eventually is
opened through the bacterial steroid metabolism pathway. Created in ChemDraw.
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The specific positions between the domains of KshA and KshB that are important to electron
transfer amid them are unclear. Knowing the spots that are the most crucial to their cooperativity
would give more information on where the electron transfer from KshB to KshA happens and give
more information on how the two proteins collaborate. Understanding how the interaction occurs
would allow knowledge to be gained on how to stop the interaction as well, which can help prevent
the development of a disease especially in the strains that are resistant to antibiotics. Prior research
conducted on the structure of the KshAB enzyme, conducted by Christian Santos, concluded
through Native-PAGE and size-exclusion chromatography (SEC) studies that the complex is likely
in a KshA3*3KshB form with additional aggregation of a higher molecular weight protein complex
(Figure 5).

Figure 5. Predicted KshAB structure, with KshA in blue and KshB in green. Three KshA
subunits creating a trimer with a subunit of KshB interacting with each KshA counterpart,
creating the KshA3*3KshB structure.
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Dr. Sarah Soltau started the investigation of the electron transport between the two subunits, and
students in her research group have attempted to look at certain sites within the KSH enzyme to
find possible critical electron transfer sites. I have examined the crystal structures of KshA and
KshB through PyMOL, a computer software program, that allowed me to measure the distances
between the amino acids (the building blocks of all proteins) in a model of KshAB. I chose several
that are close in proximity, which can signify a possible important interaction, and decided on an
arginine residue at position 286 of KshB to mutate. This decision was made because the one amino
acid had close interactions three separate amino acids on one of the KshA subunits, measuring
only 1.9Å to a glycine at position 71. Existence of these amino acids in close proximity can allow
for intermolecular forces (IMFs) between the two proteins. IMFs can influence the interaction
between molecules through the forces of attraction, repulsion, or stabilization (20). Therefore,
mutating that amino acid at the 286th position could break any IMFs possibly existing with KshA’s
glycine at residue 71, causing destabilization and loss of electron transfer.

The arginine at the 286th position of the KshB protein was mutated to two different amino acids
through a process called mutagenesis. Arginine has a basic composition because of its amine
substituents (nitrogen and hydrogen groups) and is also a large molecule when compared to other
amino acids (Figure 6). Arginine also has a positive charge on its side chain, which will likely be
used to transport negatively charged electrons (21). The first mutation will change arginine to
alanine. Alanine is a neutral compound that is nonpolar with a small side group (Figure 6). This
mutation will cause that site to lose affinity towards negatively charged electrons (21). The
decrease in size can lessen the strength of their interaction between KshA and KshB as well. The
second mutation will change arginine 286 to an aspartic acid. As previously mentioned, arginine
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is basic in composition so the change from a basic to an acidic compound will disrupt many
interactions and possibly change the folding of that area of the protein. Aspartic acid also has a
negative charge on its side chain, which will repel electrons away and not allow for electron
transport (21). Refer to Figure 6 to see the differences between the three amino acids discussed.

Figure 6. Chart of all amino acid side chain structures and their physical properties, with
the black-boxed amino acids showing the three that were involved in the specific mutation.
KshB-WT contains arginine. The two mutations applied through mutagenesis will change
that amino acid to alanine, which is denoted as R286A, and aspartate, whose mutation is
known as R286D (22).
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Mutagenesis is a biochemical technique that changes the genetic information of an organism to
produce desired mutations (21). Since the code for the KshAB gene is known, it is fairly easy to
change base pairs to produce the mutations wanted. Primers containing the changed DNA for the
alanine and aspartic acid mutants were designed and ordered, and mutagenesis allowed for these
mutations to be grown into an abundance of mutant proteins within super-competent cells. Supercompetent cells can then be transformed into DH5 cells to allow for preparation of expression
plasmids use to express and purify the protein of interest (21).

Mutation of a site that is essential to electron transfer would cause a lack of interaction and a break
in IMFs, therefore preventing the breakdown of cholesterol and stopping energy production for M.
tuberculosis bacteria via this pathway. Thanks to the potential for interrupting the electron transfer
pathway with specific mutations, two mutations were prepared at the 286th site within KshB.
Mutations to both alanine and aspartic acid were inserted into bacteria, expressed, purified, and
concentrated. The enzymatic activity of aspartic acid mutant was kinetically analyzed for its
effectiveness in blocking the electron transfer within the KshAB enzyme, and later compared to
kinetic data obtained for the wildtype KshAB complex. If the mutations at the arginine residue to
an acidic residue bring a loss of kinetic activity, compounds or drugs could be developed to
introduce a block between KshAB at that site. Blocking that site will inhibit the electron transfer
between the two subunits, which will shorten the length of TB infection in affected patients. This
would diminish the number of TB cases world-wide (including MDR and XDR strains since it
won’t involve antibiotic treatment), prolong the lifespan of those infected, and alleviate the
burdens of consumption-related deaths internationally.
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Methods
Mutagenesis of KshB mutants: R286A & R286D. The following primers were ordered from
Invitrogen for the KshB-R286A and KshB-R286D mutations, respectively.

Figure 7. Primer sequences for KshB-R286A along with oligonucleotide information. Both
primers are shown in the 5’ to 3’ direction and are 34 nucleotides in length. These primers
were designed using the known genetic sequence of the KshB gene and the QuikChange
Primer Design tool at https://www.chem.agilent.com/store/primerDesignProgram.jsp.

Figure 8. Primer sequences for KshB-R286D along with oligonucleotide information. Both
primers are shown in the 5’ to 3’ direction and are 36 nucleotides in length. These primers
were designed using the known genetic sequence of the KshB gene and the QuikChange
Primer Design tool at https://www.chem.agilent.com/store/primerDesignProgram.jsp.
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A QuikChange II Site-Directed Mutagenesis Kit (Agilent) was used to insert those primers into
super-competent cells, which allowed the cells to accept those mutations as normal and therefore
created the unmutated KshA and mutated KshB proteins. The KshB-R286A and KshB-R286D
reactions were subjected to thermocycling Pfu Ultra Polymerase, dNTPs, and wtKshB plasmid.
Each reaction underwent thermocycling using the protocol in Table 1.

Table 1. Thermocycling parameters for QuikChange II Site-Directed Mutagenesis
(Agilent). Segment Two was run for 16 cycles since each primer had a single amino acid
change only.

After thermocycling, the reactions were digested with the restriction enzyme DpnI for 1 hour at
37°C to remove parental DNA and then transformed into super-competent cells on LB plates
containing Kanamycin along with positive and negative controls that grew on LB plates containing
Ampicillin. Growth was allowed to occur overnight at 37°C, and the R286D and R286A plates
both had colonies, expected to be the mutated protein. These colonies were used to create LBKanamycin starter cultures to create more plasmids via a plasmid prep using the GeneJet Plasmid
Mini-Prep Kit (ThermoFisher), and their concentrations and purity were determined using a diode
array UV-Vis Spectrophotometer using the absorbances at 260 and 280 nm. Subsequent plasmid
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preparations were performed in DH5α cells using the procedures above and these plasmids were
used for protein expression.

Expression of KshA-WT, KshB-WT, & KshB-Mutants. Ten LB-Kanamycin starter cultures of the
wildtype proteins were prepared the night before in BL21-DE3 competent cells and left in the
shaker overnight at 37°C. Flasks containing a total of 4.5 L worth of media were autoclaved then
placed in another shaker the night before as well. Mineral stocks (HCl-solubilized solution of
minerals containing 14.1 mM MgCl2•6H2O, 2.5 mM CaCO3, 4.27 mM FeSO4•7H2O, 0.625 mM
ZnSO4•7H2O, 0.625 mM MnSO4•H2O, 0.125 mM CuSO4•5H2O, 0.125 mM CoCl2•5H2O, 0.125
mM H3BO3, 262.5 mM MgSO4, 10 mM CaCl2, and 0.1 mM thiamine) (23), kanamycin, and a
starter culture was added to each of the flasks after overnight incubation, and cell proliferation was
recorded through intermittent absorbance readings at 600 nm while growth was occurring at 30°C.
Once there were enough cells grown (OD600 between 0.6 and 0.8) in E. coli, the flasks were all
induced with isopropyl β-d-1-thiogalactopyranoside (IPTG) and left to incubate with shaking at
200 rpm overnight at 25°C. Centrifugation at 8000 rpm and 4°C for 10 minutes was used to harvest
the cells the next day. The cells were localized to the bottom of the tubes used, which allowed for
accumulation and easier collection. The total mass of cells accumulated were obtained and they
were subsequently resuspended in a 20mM potassium phosphate/10% glycerol/pH 8.0 buffer
solution and stored in the -80°C freezer. This method was performed to provide an over-abundance
of cells that have produced a significant amount of the proteins we are interested in studying,
allowing for several trials of experimentation and analysis.
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Purification of KshA-WT, KshB-WT, & KshB-Mutants. Cells from expression methods were lysed
(broken open) after a 30-minute incubation on ice with phenylmethylsulfonylfluoride (PMSF) and
lysozyme to break the cell walls. Sonication was performed a total of six rounds of 30 seconds
each in order to rupture cells, with a five-minute break on ice between each cycle for each solution.
Sonication uses an apparatus that emits ultrasonic waves that can break cell membranes through
the waves’ vibrations (21). Centrifugation was used again in a Sorvall small rotor centrifuge at
18,000 rpm for 30 minutes at 4°C to separate the cell debris and collect the cell contents. Solutions
of the supernatant collected were run in a 4°C cold room through a His-Pur Nickel-NTA column
(Thermo-Fisher) pre-equilibrated with a 20 mM potassium phosphate/10 mM imidazole/10%
glycerol/pH 8.0 buffer. This method eluted cell contents over time via gravity while binding to our
KshA/KshB proteins of interest, thus preventing a large amount of impurities. The first set of
eluted fractions were “flow-through”, which was when the supernatant was run through the
column, allowing most impurities to run through the column. Next was a wash step, which used
30 mL of wash buffer (20 mM potassium phosphate/25 mM imidazole/10% glycerol/pH 8.0) in
each column to “wash away” extra impurities that could still be on the column after the first step.
The last of those collected the protein of interest using 60 mL of elution buffer (20 mM potassium
phosphate/250 mM imidazole/10% glycerol/pH 8.0) in each column to detach the binding between
the Nickel-NTA beads and the proteins. Each of the eluted solutions were stored in the cold room
at 4°C overnight for further analysis of purity and presence of KshA/KshB through SDS PAGE.
Gels from the SDS-PAGE experiments performed were later imaged for further examination.
These methods were used to isolate our protein of interest for further experiments and to determine
the general amount of purity of each of the protein samples. Purification of the mutant KshB
proteins follow the same protocol as that of the wildtype proteins.
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SDS-PAGE Gels & Concentrating. These experiments used the eluted and semi-purified solutions
gathered from Nickel-NTA chromatography purification steps. Each solution collected during the
column chromatography process was placed in a separate lane, then run at 200V for 30 minutes to
have the solutions run to the bottom of the gel at room temperature. This produced bands on the
gel based off of the proteins’ size and charge within each lane. Once the gel is removed from the
apparatus, it is stained in Coomassie blue for at least 20 minutes, then submerged in a de-staining
solution twice for 15 minutes each. Gels were imaged using the Pharos FX Imager (Bio-Rad) after
the gel sat in deionized water for 15 minutes. This method confirmed the presence of our protein
of interest in certain solutions, along with visualizing how pure each solution is based on the
presence of one or multiple bands in that lane. More unnecessary bands are linked to higher levels
of impurities (24). Whichever solutions had high purity with the presence of our protein were
further purified through a process called concentrating, which used a centrifuge and special
membrane-containing tubes that further concentrated proteins with a molecular weight more than
10 kDa. Proteins with a molecular weight less than 10 kDa were eluted through the membrane and
consequently disposed. This method overall allowed for the confirmation of the protein’s presence
and gave a general sense to how pure each solution was. The concentration of each of the hyperconcentrated protein solutions was determined using the following method.

Bradford Assay. A Bradford Assay was used to determine the concentration of protein within the
hyper-concentrated solution (21). This was done by adding Protein Assay Dye (Bio-Rad) which
binds to proteins and measuring the solution’s absorbance at 595nm after a few minutes of
incubation on a Lambda Bio+ UV-Vis Spectrophotometer (Thermo-Fisher). A standard linear
curve, generated using Bovine Serum Albumin (BSA) as a reference, was created prior to the
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Bradford and was used to determine the concentration of KshA and R286D by inputting the
measured absorbance as a method of normalization. This provided us a specific concentration for
those proteins so the measurements and solution amounts for the subsequent kinetic assays could
be determined.

Kinetic Assays of KshB-R286D. UV-Vis based assays were performed to understand the kinetics
of the KshB-Mutant’s reactivity with KshA. Kinetic assays were not performed on KshB-R286A
due to time constraints, and there was not a significant reason behind why the aspartic acid mutant
was analyzed first. As shown within Figure 3, NADH is reduced to NAD+ when KshB takes its
electrons, and then the electrons are shuttled to KshA which hydroxylates the substrate to product.
Experimentation took place within a nitrogen box as a reduced oxygen environment was required
to prevent spontaneous oxidation occurring with the air. Amounts of every reactant put into each
quartz cuvette stayed the same through all the different concentrations, with the only amount
changing was the concentration of formestane, with the buffer volume changing to accommodate
this (Table 2). The kinetic assay observed the consumption of NADH over time by measuring the
absorption of UV light at a wavelength of 340nm through the use of a diode ray UV-Vis
Spectrophotometer (Thermo-Fisher) in TimeDrive mode, collecting data point every second for
15 minutes. Slopes of kinetic traces collected on the UV-Vis were analyzed and the averages and
standard deviations calculated at each substrate concentration. Several weeks were required to
troubleshoot the UV-Vis apparatus. Various methods were performed in an attempt to
troubleshoot, such as replacing lightbulbs and cleaning the device’s interior. Program reboots and
various types of zeroing procedures proved to be unhelpful, and eventually kinetic experiments
were moved to a different location with a functional UV-Vis, which resolved all issues.
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Table 2. A portion of the kinetic solution values showing how much of each reactant should
be added to a single cuvette. Only concentrations 0.4 mM, 0.2 mM, and 0.1 mM are
depicted, but each concentration had a minimum of three solutions in cuvettes created, with
the final volume always equaling 1 mL. The stock values and wanted final concentration
of each reactant is also shown within each box.

At least three replicates were used for each value except 0.1 mM formestane, where only one value
was used. The slopes, which provided the change in absorbance per second, were converted to
kinetic units using Beer’s Law (Eq. 1) and the following conversion (Eq. 2). The value for 𝜀 is
from the NADH value of 𝜀340, which equals 6220 M-1 cm-1, and ℓ is the pathlength of the quartz
cuvette used, which was 1 cm.

∆𝐴
𝑠𝑒𝑐𝑜𝑛𝑑

∆𝐴
𝑠𝑒𝑐𝑜𝑛𝑑

×

60 𝑠𝑒𝑐𝑜𝑛𝑑𝑠
1 𝑚𝑖𝑛𝑢𝑡𝑒

×

= 𝜀 ∙ ℓ ∙ ∆𝐶

1𝑀
6220

×

1×106 𝜇𝑚𝑜𝑙
1 𝑚𝑜𝑙

(Eq. 1)

=

𝜇𝑀
𝑚𝑖𝑛𝑢𝑡𝑒

(Eq. 2)
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The rates of NADH consumption vs. formestane concentration was plotted and used to create a
Michaelis-Menten plot in the Origin 2017 program. The graph was analyzed to obtain important
values such as KM and Vmax using the Michaelis-Menten equation (Eq.3).

𝑉𝑜 =

𝑉𝑚𝑎𝑥 × [𝑆]
𝐾𝑀 + [𝑆]

(Eq. 3)

In addition, kcat was calculated via (Eq. 4) to further understand the activity of KshAB.

𝑉

𝑚𝑎𝑥
𝑘𝑐𝑎𝑡 = [𝐾𝑠ℎ𝐴 𝐸𝑛𝑧𝑦𝑚𝑒]

𝑡𝑜𝑡𝑎𝑙

(Eq. 4)

Data for the KshB-R286D mutant was compared to that obtained of the wild type KshAB complex
to evaluate for differences in enzymatic activity. The wild-type KshAB kinetic values were
initially obtained by a prior research student, Priya Patel, in Spring 2018.
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Results
Expression and Purification. It took KshA-WT cells three and a half hours to reach the desired
OD600. There was a total of 28.002 g of KshA-WT-BL21 cells after growth, producing three 40
mL solutions and one 30 mL solution of resuspended cells for sonication. Sonication and
centrifugation then produced ~135 mL of supernatant to be purified in the Nickel-NTA columns.
The purification method produced seven ~15mL “elution solutions”, each to be run on the SDSPAGE. It also took KshB-R286D-BL21 three and a half hours to reach the desired OD600 value. A
total of 31.844 g of R286D-BL21 cells were produced from the growth procedure. There were two
Falcon tubes of resuspended cells containing 40 mL and another two that had 30 mL of cells within
them for sonication. The following sonication and centrifugation steps produced ~115 mL of
supernatant to be run through the Nickel-NTA columns. Purification provided six ~15 mL “elution
solutions” to be run on the SDS-PAGE, with the second solution having the most prominent shade
of yellow out of them all. The KshB-R286A-BL21 cells took the longest to reach OD600, with the
flasks only being induced a little over four and a half hours after taking the blank. There was only
total of 17.776 g of R286A-BL21 cells grown. Purification through Nickel-NTA columns
produced six “elution solutions” that were run on SDS-PAGE gels, with the first three having a
stronger yellow-tinge than the others.

SDS-PAGE. A total of three gels were run since the KshA-WT, KshB-R286D, and KshB-R286A
proteins were expressed properly. All gels contain a protein marker in lane 2, which allowed for
approximation of the size of each band based off of the distance that they migrated from the top.
The supernatant for the KshA Ni-NTA column was not saved and therefore was not run on the
SDS-PAGE gel, but the two KshB mutants did contain the supernatant and ensured that it did not
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contain the protein. The KshA protein had a lot of contaminants, as shown by the crowded banding
patterns within each lane (Figure 9). The KshA protein is more dilute than the other two mutants,
but it was decided to still concentrate all eluted solutions since there is not a significant amount of
protein present in all the samples. R286D was most abundant in the first and second solutions
(lanes 8 and 9), therefore having higher concentrations within those two vials. The overall purity
of the R286D solutions are high except for the first solution (lane 8), as can be seen by all the
bands within that lane (Figure 10). It was decided to discard that solution since it would not provide
a significant amount of protein and would highly increase its impurity. R286A was most abundant
in the first, second, and third solutions (lanes 8, 9, and 10), therefore having higher concentrations
within those three vials. The purity is fairly high seeing as there are not significant bands outside
of the one representing the R286A protein (Figure 11).
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Figure 9. SDS-PAGE gel of KshA-WT-BL21 protein elution solutions from Ni-NTA
column chromatography. The box around the bands indicate where KshA is located on the
gel, which was determined accurately because of the Protein Marker in Lane 2, with units
in kDa. Lanes 4 and 5 contain the flow-through and wash while lanes 6-12 contain the
seven eluted solutions which contain different amounts of KshA, as outlined in red. This
photo was obtained from a Pharos FX gel imager (Bio-Rad) within the Chemistry
Department at Bridgewater State University.
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Figure 10. SDS-PAGE gel of KshB-R286D-BL21 protein elution solutions from Ni-NTA
column chromatography. The box around the bands indicate where R286D is located on
the gel, which was determined accurately because of the Protein Marker in Lane 2, with
units in kDa. The supernatant, flow-through, and wash solutions are located in lanes 4, 5,
and 6. Lanes 1, 3, and 7 were kept empty, and lanes 8-13 contain the six eluted solutions,
which contained the mutant protein. This photo was obtained from a Pharos FX gel imager
(Bio-Rad) within the Chemistry Department at Bridgewater State University.

25

250
150
100
75
50
37
25
20
15
10

Figure 11. SDS-PAGE gel of KshB-R286A-BL21 protein elution solutions from Ni-NTA
column chromatography. The box around the bands indicate where R286A is located on
the gel, which was determined accurately because of the Protein Marker in Lane 2, with
units in kDa. The supernatant, flow-through, and wash solutions are located in lanes 4, 5,
and 6. Lane 1, 3, and 7 were kept empty. Lanes 8-13 contain the six eluted solutions, which
contained the mutant protein. This photo was obtained from a Pharos FX gel imager (BioRad) within the Chemistry Department.

Bradford Assay & Standard Curve. The BSA Standard Curve was created successfully using a
reference standard of 1000 μg/mL Bovine Serum Albumin. The high R2 value of 0.9903 shown in
Figure 12 signifies that the concentrations determined from the equation are accurate. The equation
created, 𝑦 = 0.0385𝑥 − 0.0058, was used by inputting the average absorption of each sample for
the 𝑦 variable and solving for 𝑥, the concentration in µg/mL. That value was then converted to
mg/mL. The KshA protein was determined to have a concentration of 84.53 mg/mL. It was
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assumed that there was more R286D protein based off of the SDS-PAGE results, and the KshBR286D protein solution was determined to be significantly concentrated, having a value of 850.9
mg/mL which is ten-fold more concentrated than the KshA protein. It is hypothesized that the
KshB-R286A protein will be even more concentrated than the R286D protein based on the dark
and prominent bands on its SDS-PAGE gel. The concentration of the R286A protein was not
measured due to time constraints.

BSA Standard Curve

y = 0.0385x - 0.0058
R² = 0.9903
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Figure 12. BSA Standard Curve for Bradford Assay. The equation obtained from the
trendline above was used to determine the concentration of the KshA-WT protein and the
KshB-R286D protein using their ultra-concentrated solutions. Its R2 value is 0.9903 and
the equation of the linear regression is 𝑦 = 0.0385𝑥 − 0.0058.
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Kinetic Assays. Kinetic assays performed on the KshA-KshB-R286D mutant protein complex,
which measured the consumption of NADH over time as it transfers electrons to the KshB subunit.
The Michaelis-Menten plot obtained from R286D data was moderately successful, which used an
average of three or more trials except with the 1.0 mM point, which only used one trial for data
analysis. The first 180 seconds of absorption values were used to calculate the rate (Figure 13)
since it contained the steepest slope, and the average rate was determined between all trials (Figure
14). The data presented in Figure 15 has greater error than anticipated, but the overall shape is a
hyperbolic curve, which is consistent with a typical Michaelis-Menten (MM) plot displaying
saturation kinetics in enzyme systems. The scale on the y-axis is quite small which is causing the
error bars to look expansive. Kinetic values such as K m, Vmax, and kcat were calculated (Eq. 1-4)
upon analysis of the kinetic data using non-linear regression analysis with the program Origin
2017.
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Figure 13. Absorption values obtained over time of the consumption of NADH with an
initial concentration of 0.2 mM formestane. These data points are from the second trial of
the 0.2 mM formestane experiment. Experimental data between zero seconds to 180
seconds were used to fit to a linear equation, producing a slope value of −9.44994 × 10−6
Abs/sec, as shown in the trendline equation on the graph.
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NADH Consumption with [0.2 mM] Formestane
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Figure 14. Absorption values obtained over time of the consumption of NADH with an
initial concentration of 0.2 mM formestane. These data points are from all three trials of
the 0.2 mM formestane experiment. The slope of each trial is obtained from zero to 180
seconds only, with each trendline’s slopes shown in each respective equation. The three
slopes are averaged to one value (−9.26794 × 106 Abs/sec) to be used for kinetic analysis
using the MM equation.
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Figure 15. Michaelis-Menten plot of KshB-R286D mutant. This graph was created by
calculating the slope of the reaction of NADH consumption over the first 180 seconds and
that was used to obtain an initial rate for reactions with varying concentrations of
formestane, a cholesterol steroid compound. A Michaelis-Menten equation was created
from the data points, with error bars (standard deviation of the average slope value from
the several trials) noting the precision between trials from the average rate. Kinetic
variables such as KM and Vmax were calculated using this program, shown in the box.

Data collected from the kinetic assays was compared to wildtype data, which was obtained by
Priya Patel in Spring 2018. The kinetic assays were performed using the same experimental
conditions using KshB-WT instead of the KshB-R286D mutant. Comparing the two data sets
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allowed for more conclusions to be drawn from the kinetics of the R286D mutant kinetics, and
values were compared to see if more trials should have been performed if certain error bars were
extensive or if certain concentration values seemed like outliers. The two data sets were overlaid
on the same graph, shown in Figure 16, and the error bars of the mutant data set decreased so
significantly that they are barely visible. The MM curve in Figure 15 was hyperbolic, but since the
values of wildtype data were large in comparison to the mutant, it looks linear and almost inactive
in Figure 16 considering that the experiments were conducted using identical conditions.
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Figure 16. Michaelis-Menten plot with two kinetic data sets plotted. The red graph depicts
the kinetic assay data obtained by me of the R286D mutant with the wildtype KshA protein.
The black graph is data from a prior research student, Priya Patel, who performed the same
kinetic assays on the wildtype KshAB complex. In comparison to Figure 15, the error bars
of the R286D data is significantly smaller thanks to a larger y-axis range. There is an
obvious discrepancy between the two results, which is significant. Kinetic values of Vmax
and Km were calculated through the graphing program for both sets of data.

The kinetic values obtained and calculated were put into a data table (Table 3) for easier
comparison between the wildtype KshAB complex and the R286D mutant. Vmax and Km were
given by the MM graph, as shown within the boxes on the right-hand side of Figures 15 and 16,
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along with their standard deviation values. The value of kcat was calculated using Eq. 4. Vmax and
total KshA enzyme concentration values were both in mM and the final value is converted to
seconds-1 from minutes-1.

Table 3. Table containing calculated kinetic values of the mutant R286D protein in
comparison to the wildtype KshAB complex. Values for V max and Km were obtained thanks
to Equations 1-3 and from the graphing software used to fit the Michaelis-Menten plot to
the data obtained. Values of kcat were calculated using Equation 4.
Kinetic Values

wtKshA – KshB R286D

Wildtype KshAB

Vmax (µM/min)

0.0897 ± 0.00555

1.14 ± 0.0842

Km (μM)

5.79 ± 4.24

244 ± 64.5

kcat (sec -1)

9.34

119
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Discussion
Mutagenesis was conducted properly after troubleshooting for two weeks, due to fresh materials
and media without contamination. SDS-PAGE gels allowed for generalized confirmation that our
protein of interest was obtained and purified (Figures 9-11). KshA-WT, R286D, and R286A were
successfully expressed, grown, and purified through Ni-NTA column chromatography as shown
by the high yield of cells containing R286A and R286D grown and the intense bands on the SDSPAGE gels. The Bradford Assay proved to be accurate as the R-squared value was 99% (Figure
12), ensuring that the calculated concentrations of each protein were precise.

Kinetic assays of KshA/KshB-R286D were conducted successfully after troubleshooting the UVVis apparatus. The slopes of these kinetic assays, specifically from the first 180 seconds, were
extrapolated into a Michaelis-Menten plot for further kinetic analysis. The Michaelis-Menten
graph was analyzed to obtain important values such as K M, Vmax, and kcat using Equations 1-4.
Since kcat represents the amount of substrate molecules converted by an enzyme per second, a
higher value for kcat indicates a higher number of substrate compounds that get oxidized every
second (21). This correlation of kcat and reaction rate is true for every enzyme complex. Vmax values
represent the rate of the reaction when the majority of enzymes have become saturated with its
substrate, in this case formestane within KshAB. K M represents the concentration of substrate that
it takes the enzyme to reach half of Vmax (21). Its small value of 5.80 µM is encouraging, since it
represents a high affinity of the substrate to the protein.

When compared to the KshAB-WT complex, the R286D mutant’s affinity to a cholesterol-like
substrate is about 50 times less, meaning that the overall function of the enzyme complex was
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decreased 50-fold. The kcat value of 9.34 s-1 for the mutant protein is significantly lower than the
wildtype KshAB complex at 119 s-1, which means that the mutant’s value is ~7% the value of the
wildtype (Table 1). This translates to ~93% less formestane undergoing oxidation with the
mutation than without it.

Overall, this finding concludes that the mutation of the arginine at position 286 to aspartic acid
caused enough change to the active site of the KshB subunit that the overall KshAB protein can
no longer work as efficiently. Arginine’s long side chain (Figure 6) has several close interactions
with the KshA subunit, as discussed in the introduction. Figure 17 further displays these
interactions, with measurements between arginine and nearby amino acids as close as 1.9 Å. The
mutation to aspartic acid, an amino acid with a shorter and oppositely charged side chain, increases
that distance between the KshA and KshB subunits and effects charge stabilization in the complex.
The larger distance prevents the potential for hydrogen bond formation and van der Waals
interactions, as the -NH2 within arginine’s structure likely experienced in order to aid in electron
transfer (Figure 6). The other potential for hydrogen bond formation between the two subunits was
at the -NH- within arginine, which was only 2.5 Å away from an oxygen in the KshA subunit. This
was more than likely disturbed because of the mutation to aspartic acid as well, as the side chain
is both too short to interact with the KshA subunit, and the closest parts of that amino acid to KshA
are oxygens. Overall, the reduction in activity seen with the R286D mutant is currently attributed
to both the loss of a positive charge and the presence of a negative charge both disrupting its ability
to accommodate electron transfer. Many other interactions between the two subunits obviously
could have been disrupted such as IMFs because of the change from arginine to aspartic acid,
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which can be a likely cause as to why the values of kinetic parameters are so different between the
WT and mutant proteins and therefore decreasing the KshAB enzyme’s overall efficiency.

Figure 17. Crystal structure of KshAB showing the mutagenesis from arginine to aspartic
acid and its interactions with KshA. The green tube-like structure are the hydrocarbons
from the KshB subunit, with the peptide bond at the 286th position highlighted. Aspartic
acid’s hydrocarbons are shown in grey, while the original arginine is still green. The KshA
subunit is throughout the background of the photo, shown in grey/blue/red sticks. Red
depicts oxygens while blue shows nitrogen. Several measurements of certain parts of the
arginine to KshA are shown in Angstroms (1.9 Å, 2.5 Å, and 2.8 Å).

The Michaelis-Menten graph has a proper hyperbolic curve shape (Figure 15), as expected for
enzymes that follow Michaelis-Menten kinetics. We can draw certain conclusions from the graph
and its kinetic values. A hyperbolic curve is ideal since it plots the rate of the oxidation reaction
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occurring with NADH against the concentration of substrate, and an enzyme typically accelerates
a reaction in a hyperbolic fashion (21). It can be drawn from the change in the rate of reaction that
this mutation to an aspartic acid decreased the protein’s ability to catalyze the breakdown of
cholesterol-like molecules. Although the breakdown of cholesterol was drastically decreased, it
was not halted completely. This is still progress, however, and when comparing the kinetic values
(Table 3) and MM graphs between the mutant and the wildtype complex (Figure 16), it becomes
more obvious that the decrease in the enzyme’s efficiency due to mutation is significant. It can be
deduced that this specific amino acid at the 286th position was significant to the electron transfer
between the A and B subunits of KshAB, and mutation to aspartic acid prevented IMFs from
occurring.

While these results are promising, more research needs to be continued to either create an even
more efficient mutation or to confirm these results. Kinetic assays have not been conducted using
the alanine mutation (R286A), and it’s hypothesized that it will also decrease the efficiency of the
protein but not to the extent of the R286D mutant because of aspartic acid’s opposite chemical
properties in comparison to alanine’s neutral chemical composition (Figure 6). Another MichaelisMenten graph should be created that compares the R286A mutant to the R286D mutant to either
confirm or reject the hypothesis, and it should also be compared to the wildtype data. Kinetic
values between all three should also be contrasted. It is also recommended to get more kinetic data
for the wildtype KshAB protein to lower the error bars and to ensure the validity of its kinetic data.
Further kinetic experimentation can lower error bars, and the information gained from that can be
used for larger-scale experiments which can kickstart the creation of a treatment for tuberculosis.
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There are many opportunities for future experimentation based off of the mutant wtKshA-KshBR286D complex regarding its thermal stability. Further work should investigate if the reduction of
catalysis in this mutant enzyme was due to the change of charge through mutagenesis or due to
thermal instability caused by this mutation. This could be investigated by several methods. Size
exclusion chromatography could be performed to confirm the complex’s size and shape, ensuring
that the two subunits are still interacting at some level and compare it to prior SEC data obtained
by Christian Santos on the wtKshAB enzyme to see if the mutation changes the overall shape and
size of the enzyme complex. To examine protein unfolding, temperature dependent fluorescence
spectroscopy or circular dichroism (CD) spectroscopy can be used on both the mutant KshB
subunit and the wtKshA-KshB-R286D complex. These methods could also be used to see if the
WT and mutant KshAB complexes have the same melting temperatures, which could give insight
to whether the mutant has denatured protein aggregates or if it stays structurally intact (21). Similar
experimentation could be done with native gels that contain increasingly concentrated amounts of
chaotropic agents, such as urea or guanidinium HCl. Those methods could be performed with the
wtKshB, R286D mutant, and the R286A mutant to contrast the differences between the various
KshB subunits created.

Additional promising experimentation of the KshAB complex includes electrochemistry
experiments, which will flow KshA onto an electrode with a current run through that contains
KshB or KshB-Mutant. This will measure the differences in electron transfer between the KshBWT and KshB-Mutant since current is the flow of electrons. Doing this to further compare the
wildtype to the R286D protein will hopefully further confirm the conclusions made in this project.
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If the current is different between the mutant and wildtype KshB, it can be concluded that the
mutation at position 286 truly disrupts the electron transfer between subunits.

It’s also possible to perform experiments within other bacteria more similar to M. tuberculosis than
E. coli to compare the growth rates of bacteria with the mutation versus those with the wildtype
KshAB complex. Experiments could possibly be done on other pathogenic bacteria that also use
this enzyme complex such as those within the actinobacteria class. Some actinobacterial pathogens
include Mycobacterium leprae which causes leprosy, Mycobacterium ulcerans that produces
Buruli ulcers, and Corynebacterium diphtheriae that is the cause of diphtheria (25). It is possible
to conduct these experiments with other bacteria within the actinobacteria class that are safer to
conduct experiments on within a lab setting, such as those that are not pathogenic. These
experiments would use the mutated KshB enzyme to compare how this effects growth rate and
cholesterol breakdown for energy on a larger organismal scale. It is also possible to align the
genetic sequences of several actinobacteria and compare the number of conserved genes and
sequences between them all and see if there is a trend between pathogenic and non-pathogenic
bacteria.

Knowing that the R286D mutation decreased the amount of oxidized formestane substrate is
enough of a reason to start looking into implementing this mutation as a form of small-molecule
treatment in cases of tuberculosis since it does not involve antibiotic treatment, so MDR and XDR
strains will no longer be an issue. This could possibly be done through creating a small molecule
that blocks the interaction between the two subunits at position 286 of KshB in a similar way to
the aspartic acid blocking. There would be high specificity for this small molecule, as it would
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need to bind to a specific region within the KshB subunit instead of any other protein in the human
body. It would also have to contain many negatively charged groups to further prevent electrons
from passing between each subunit.

Although treatment with this mutation would not eradicate the disease, it can slow the progression
by preventing the bacterium from producing energy at its normal rate, which will decrease its rate
of proliferation and therefore either shorten the duration of symptoms, make it more manageable,
or allow for other treatments to eradicate the infection by lowering the threshold of bacteria
present.
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